mProX™ Human PRLHR Stable Cell Line

Product Information

Target Protein

PRLHR

Target Family

Prolactin-releasing Peptide Family

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

GPCR Cell Lines

Target Research Area

CNS Research; Reproductive Research

Related Diseases

Body Mass Index Quantitative Trait Locus

Gene ID

2834

UniProt ID

P49683

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Because PRLHR has been identified as a prolactin-releasing peptide receptor, prolactin-releasing peptide mediates its activation. Pituitary PRLHR is highly expressed and contributes to the development of fibroids. AKT and MTOR were activated by the elevated expression of PRLHR in the patient's leiomyoma samples. When patients' leiomyoma cells are treated with PrRP-31 peptide, their PI3K/AKT/MTOR signaling and proliferation increase in comparison to healthy smooth muscle cells obtained from the myometrium. According to other findings, PRLHR and other connected factors have a significant influence in metabolic diseases. Numerous studies also point to the importance of the PrRP and PRLHR signaling pathway in the homeostatic control of eating and energy balance. The customized PRLHR stable cell line can be used in potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Anna

High quality and reliable PRLHR cell line. Apr 18 2023

chat Verified Customer

chat Mason

We want to stick to the same system. Feb 15 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Prlhr localizes to cilia in the hypothalamic third ventricle.

In the adult mouse brain, Prlhr was confined to the ventricular cilium. An anti-Prlhr antibody (green) was used to immunostain frozen slices of the adult mouse brain that included the third ventricle. In cilia sticking out from cells on the third ventricle's surface, the Prlhr signal was seen.

Ref: Omori, Yoshihiro, et al. "Identification of G protein-coupled receptors (GPCRs) in primary cilia and their possible involvement in body weight control." PloS one 10.6 (2015): e0128422.

Pubmed: 26053317

DOI: 10.1371/journal.pone.0128422

Research Highlights

A helpful biomarker for determining the prognosis and effectiveness of immune checkpoint inhibitors (ICIs) is tumor mutation burden (TMB). A novel therapeutic target for the treatment of glioma patients and an increase in their survival rate may be provided by PRLHR, which may act as a tumor suppressor for the growth of the disease.
Liu, Yi, et al. "PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas." Frontiers in Oncology 12 (2022): 620190.
Pubmed: 35800054 DOI: 10.3389/fonc.2022.620190

The investigation of the spectrum of PRL, PRLR, and PRLHR gene variations in women of reproductive age with nontumor hyperprolactinemia was the main objective of the study. PRL, PRLR, and PRLHR genes underwent targeted high throughput sequencing in women with hyperprolactinemia of nontumor etiology.
Shakhtshneider, E. V., et al. "Results of Targeted Sequencing of PRL, PRLR, and PRLHR Genes in Young Women with Nonneoplastic Hyperprolactinemia." Cell and Tissue Biology 17.3 (2023): 292-298.